Phase 1 tolerability and antiamoebic activity studies with 1-methylsulphonyl-3-(1-methyl-5-nitro-2-imidazolyl)-2-imidazolidinone (Go.10213): a new antiprotozoal agent.

Go.10213, a new nitroimidazole, was studied in 12 male volunteers for tolerability and in 20 patients with intestinal amoebiasis for antiamoebic activity. Go.10213 was well-tolerated by volunteers up to a dose of 400 mg X 3. Patients also tolerated well the dose of 100-150 mg X 3 for 7 days. In two...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Vaidya, A B, Ray, D K, Mankodi, N A, Paul, T, Sheth, U K
Médium: Artigo
Jazyk:Inglês
Vydáno: 1983
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1428073/
https://ncbi.nlm.nih.gov/pubmed/6639838
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky